Literature DB >> 20412712

Defective FOXP3 expression in patients with acute Kawasaki disease and restoration by intravenous immunoglobulin therapy.

Biagio Olivito1, Andrea Taddio, Gabriele Simonini, Cristina Massai, Sara Ciullini, Eleonora Gambineri, Maurizio de Martino, Chiara Azzari, Rolando Cimaz.   

Abstract

OBJECTIVES: The aims of this study were: 1) to investigate forkhead box P3 (FOXP3) expression in patients with Kawasaki disease (KD), exploring possible differences during the acute phase and after defervescence; 2) to evaluate a possible association of the FOXP3 single nucleotide polymorphism (SNP) 543 (SNP ID: rs2232367) with KD.
METHODS: FOXP3 expression was evaluated on 8 children with KD and 15 healthy children by flow cytometry and Real-Time polymerase chain reaction (RT-PCR). FOXP3 SNP 543 was genotyped by denaturing high-performance liquid chromatography (DHPLC) and sequencing on DNA samples from 58 additional children with KD and 114 healthy donors.
RESULTS: The frequencies of CD4+CD25 +FOXP3+ regulatory T cells were significantly (p=0.0002) lower during the acute phase of KD than in sex- and age-matched healthy donors (median % + SD: 4.8+/-1.3 vs. 7.7+/-1.7) and a similar tendency was revealed for FOXP3 mRNA transcripts (p<0.0001). FOXP3 expression increased significantly, at both protein and mRNA levels, after intravenous immunoglobulin (IVIG) therapy treatment and achieving complete remission of disease (at least 48 hrs; median 9.5 days, range 2-30). Of the 58 patients screened, only one female subject (1.7%) carried the presence of 543 SNP in heterozygosis (C>T; for a total of 1 allele out of 88), with no difference between KD patients and controls (0.0%, 0/203 alleles).
CONCLUSIONS: Our data reinforce the notion of an impaired immunoregulation in KD, suggesting also a role of IVIG treatment in modifying the Treg compartment. FOXP3 SNP 543 does not seem to be involved in susceptibility to KD in Italian children.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20412712

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  19 in total

1.  Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients.

Authors:  Mohan S Maddur; Magalie Rabin; Pushpa Hegde; Francis Bolgert; Moneger Guy; Jean-Michel Vallat; Laurent Magy; Jagadeesh Bayry; Srini V Kaveri
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

Review 2.  Impact of Immunoglobulin Therapy in Pediatric Disease: a Review of Immune Mechanisms.

Authors:  Priscilla H Wong; Kevin M White
Journal:  Clin Rev Allergy Immunol       Date:  2016-12       Impact factor: 8.667

Review 3.  Intravenous immunoglobulin therapy in rheumatic diseases.

Authors:  Jagadeesh Bayry; Vir Singh Negi; Srini V Kaveri
Journal:  Nat Rev Rheumatol       Date:  2011-05-10       Impact factor: 20.543

4.  Broadened T-cell repertoire diversity in ivIg-treated SLE patients is also related to the individual status of regulatory T-cells.

Authors:  Nuno Costa; Ana E Pires; Ana M Gabriel; Luiz F Goulart; Clara Pereira; Bárbara Leal; Ana C Queiros; Wahiba Chaara; Maria F Moraes-Fontes; Carlos Vasconcelos; Carlos Ferreira; Jorge Martins; Marina Bastos; Maria J Santos; Maria A Pereira; Berta Martins; Margarida Lima; Cristina João; Adrien Six; Jocelyne Demengeot; Constantin Fesel
Journal:  J Clin Immunol       Date:  2012-10-14       Impact factor: 8.317

5.  Lack of CD4⁺CD25⁺FOXP3⁺ regulatory T cells is associated with resistance to intravenous immunoglobulin therapy in patients with Kawasaki disease.

Authors:  Yu Hirabayashi; Yoshiyuki Takahashi; Yinyan Xu; Kazuyuki Akane; Itzel Bustos Villalobos; Yusuke Okuno; Shinji Hasegawa; Hideki Muramatsu; Asahito Hama; Taichi Kato; Seiji Kojima
Journal:  Eur J Pediatr       Date:  2013-01-23       Impact factor: 3.183

6.  Regulatory T cell microRNA expression changes in children with acute Kawasaki disease.

Authors:  F-F Ni; C-R Li; Q Li; Y Xia; G-B Wang; J Yang
Journal:  Clin Exp Immunol       Date:  2014-11       Impact factor: 4.330

7.  Patients treated with high-dose intravenous immunoglobulin show selective activation of regulatory T cells.

Authors:  A S W Tjon; T Tha-In; H J Metselaar; R van Gent; L J W van der Laan; Z M A Groothuismink; P A W te Boekhorst; P M van Hagen; J Kwekkeboom
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

Review 8.  Interleukin-2 and regulatory T cells in rheumatic diseases.

Authors:  Antonios G A Kolios; George C Tsokos; David Klatzmann
Journal:  Nat Rev Rheumatol       Date:  2021-11-02       Impact factor: 20.543

9.  High Dose Intravenous IgG Therapy Modulates Multiple NK Cell and T Cell Functions in Patients With Immune Dysregulation.

Authors:  Sarah M McAlpine; Sarah E Roberts; John J Heath; Fabian Käsermann; Andrew C Issekutz; Thomas B Issekutz; Beata Derfalvi
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

Review 10.  Epigenetics in Kawasaki Disease.

Authors:  Kaushal Sharma; Pandiarajan Vignesh; Priyanka Srivastava; Jyoti Sharma; Himanshi Chaudhary; Sanjib Mondal; Anupriya Kaur; Harvinder Kaur; Surjit Singh
Journal:  Front Pediatr       Date:  2021-06-25       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.